1. Home
  2. XRX vs AKBA Comparison

XRX vs AKBA Comparison

Compare XRX & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Xerox Holdings Corporation

XRX

Xerox Holdings Corporation

HOLD

Current Price

$3.26

Market Cap

368.8M

Sector

Technology

ML Signal

HOLD

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$0.90

Market Cap

343.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XRX
AKBA
Founded
1906
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Computer peripheral equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
368.8M
343.4M
IPO Year
2019
2014

Fundamental Metrics

Financial Performance
Metric
XRX
AKBA
Price
$3.26
$0.90
Analyst Decision
Hold
Strong Buy
Analyst Count
1
3
Target Price
$2.50
$4.67
AVG Volume (30 Days)
3.7M
3.2M
Earning Date
04-30-2026
05-07-2026
Dividend Yield
6.31%
N/A
EPS Growth
23.26
93.94
EPS
N/A
N/A
Revenue
$117,000,000.00
N/A
Revenue This Year
$8.96
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.19
$0.82
52 Week High
$4.42
$3.44

Technical Indicators

Market Signals
Indicator
XRX
AKBA
Relative Strength Index (RSI) 57.71 29.48
Support Level $2.40 $0.85
Resistance Level $3.74 $1.54
Average True Range (ATR) 0.25 0.07
MACD 0.06 -0.03
Stochastic Oscillator 55.91 19.68

Price Performance

Historical Comparison
XRX
AKBA

About XRX Xerox Holdings Corporation

Xerox Holdings Corp is a workplace technology company, building and integrating services-led, software-enabled, workplace solutions for enterprises large and small. It provide advance document technology, services, software, and integrated IT infrastructure solutions for a range of customers including small and mid-sized businesses, large enterprises, governments and graphic communications providers, and for partners who serve them. Xerox serves customers globally in North America, Europe, Latin America, Brazil, Asia Pacific (APAC), the Middle East, Africa, and India.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

Share on Social Networks: